Skip to content
Menu

HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target

Benzinga Newsdesk 9 hours ago

Analyst RatingsNewsReiterationPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.

Read at benzinga.com